# Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule

Study · id `cardio:ct-nct07508618` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07508618](<https://clinicaltrials.gov/study/NCT07508618>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07508618

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 846 participants.

## Technical summary

Registry record NCT07508618. Randomized; quadruple masking; primary purpose prevention. Start 2026-02-09 (actual); primary completion 2027-08-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 846 participants (planned count; ClinicalTrials.gov record NCT07508618, source copy `cardio:ctgov-nct07508618-2026-04-02`, retrieved 2026-10-26)
- Started: 2026-02-09 (actual) (ClinicalTrials.gov record NCT07508618, source copy `cardio:ctgov-nct07508618-2026-04-02`, retrieved 2026-10-26)
- Primary completion: 2027-08-30 (anticipated) (ClinicalTrials.gov record NCT07508618, source copy `cardio:ctgov-nct07508618-2026-04-02`, retrieved 2026-10-26)
- Completion: 2027-08-30 (anticipated) (ClinicalTrials.gov record NCT07508618, source copy `cardio:ctgov-nct07508618-2026-04-02`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07508618, source copy `cardio:ctgov-nct07508618-2026-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07508618-2026-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule
- Acronym: QDYX-AF
- Condition: Persistent Atrial Fibrillation
- Intervention (Drug): Qi Dong Yi Xin Granules
- Intervention (Drug): Placebo
- Lead sponsor: Sir Run Run Shaw Hospital
- Lead sponsor class: OTHER
- Collaborator: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Sir Run Run Shaw Hospital (`cardio:org-sir-run-run-shaw-hospital`)
- Registry lists this organization as a collaborator: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (`cardio:org-hangzhou-zhongmei-huadong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 76f5d1a6c1160d42e4bb1b45a22ee17fa2910d0ee6350b6f56e22af938b43a34
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
